Cour Pharmaceuticals Secures $900 Million Licensing Agreement with Roche's Genentech

Cour Pharmaceuticals Development Co., Inc. , a Chicago-based biotech startup, has announced a significant licensing agreement with Genentech , a subsidiary of Roche. This strategic collaboration, valued at over $900 million, aims to develop and commercialize Cour's innovative tolerogenic nanoparticle treatments for an undisclosed autoimmune disease. ??

The agreement outlines that Cour Pharmaceuticals will handle the preclinical development and technical transfer of manufacturing, while Genentech will be responsible for clinical development, regulatory filing, and commercialization. Cour is set to receive upfront and near-term milestone payments totaling $40 million, with the potential to earn additional payments based on development, commercial, and net sales milestones, ultimately exceeding $900 million. Additionally, Cour will receive tiered royalties on net sales.??

Founded in 2013, Cour Pharmaceuticals is focused on developing novel reverse vaccines that reprogram the body's white blood cells to avoid attacking healthy organs. The company's proprietary technology, developed at Northwestern University - The Feinberg School of Medicine , leverages biodegradable nanoparticles that encapsulate specific antigens. Cour is currently working on phase 2 programs for myasthenia gravis and primary biliary cholangitis, as well as a type 1 diabetes prospect. ????

This collaboration with Genentech is not Cour's first major partnership. Earlier this year, Cour raised $105 million in a Series A funding round co-led by Lumira Ventures and Alpha Wave Global Ventures, with contributions from the Roche Venture Fund, 辉瑞 Breakthrough Growth Initiative, 百时美施贵宝 , Angelini Ventures , and the JDRF T1D Fund. The company has also partnered with Takeda Pharmaceuticals on a therapy for celiac disease, valued at up to $420 million. ????

#Biotech #Pharmaceuticals #AutoimmuneDiseases #GeneTherapy #CourPharmaceuticals #Genentech #Roche #MedicalResearch #HealthInnovation #Nanotechnology